ES2182175T3 - Utilizacion de un derivado del alquilenodioxibenceno para el tratamiento de los trastornos del ritmo circadiano del sueño. - Google Patents

Utilizacion de un derivado del alquilenodioxibenceno para el tratamiento de los trastornos del ritmo circadiano del sueño.

Info

Publication number
ES2182175T3
ES2182175T3 ES98109003T ES98109003T ES2182175T3 ES 2182175 T3 ES2182175 T3 ES 2182175T3 ES 98109003 T ES98109003 T ES 98109003T ES 98109003 T ES98109003 T ES 98109003T ES 2182175 T3 ES2182175 T3 ES 2182175T3
Authority
ES
Spain
Prior art keywords
circadian
sleep
alkyleneodioxibencen
disorders
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98109003T
Other languages
English (en)
Inventor
Shigenobu Shibata
Takahiro Moriya
Michikazu Abe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Chemical Corp
Original Assignee
Mitsubishi Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Chemical Corp filed Critical Mitsubishi Chemical Corp
Application granted granted Critical
Publication of ES2182175T3 publication Critical patent/ES2182175T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

SE DESCRIBE UN MEDICAMENTO PREVENTIVO Y/O TERAPEUTICO PARA LOS TRASTORNOS DEL SUEÑO RELACIONADOS CON EL RITMO CIRCADIANO, TAL COMO EL SINDROME DEL JET - LAG, QUE INCLUYE COMO INGREDIENTE ACTIVO UN DERIVADO DE ALQUILENDIOXIBENCENO REPRESENTADO POR LA SIGUIENTE FORMULA (I), EN LA CUAL M REPRESENTA UN NUMERO ENTERO DE 2 A 5, Y N REPRESENTA UN NUMERO ENTERO DE 1 A 3, TAL COMO EL 5 - [3 - [(2S) - (1,4 - BENZODIOXAN - 2 - ILMETIL)AMINO]PROPOXI] - 1,3 - BENZODIOXOL, O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO.
ES98109003T 1997-05-20 1998-05-18 Utilizacion de un derivado del alquilenodioxibenceno para el tratamiento de los trastornos del ritmo circadiano del sueño. Expired - Lifetime ES2182175T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP12916197 1997-05-20

Publications (1)

Publication Number Publication Date
ES2182175T3 true ES2182175T3 (es) 2003-03-01

Family

ID=15002661

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98109003T Expired - Lifetime ES2182175T3 (es) 1997-05-20 1998-05-18 Utilizacion de un derivado del alquilenodioxibenceno para el tratamiento de los trastornos del ritmo circadiano del sueño.

Country Status (5)

Country Link
US (1) US6160005A (es)
EP (1) EP0884049B1 (es)
CA (1) CA2238065C (es)
DE (1) DE69807586T2 (es)
ES (1) ES2182175T3 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999008675A1 (en) 1997-08-19 1999-02-25 Mitsubishi Chemical Corporation Remedies for irritable bowel syndrome
JP4808612B2 (ja) * 2003-04-25 2011-11-02 田辺三菱製薬株式会社 アルキレンジオキシベンゼン誘導体を含む経口投与用組成物
CN101120002A (zh) 2005-02-17 2008-02-06 惠氏公司 环烷基稠合的吲哚、苯并噻吩、苯并呋喃和茚衍生物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684739A (en) * 1980-12-15 1987-08-04 Mitsubishi Chemical Industries Limited Alkylenedioxybenzene derivatives and acid addition salts thereof
JPH03264528A (ja) * 1990-03-14 1991-11-25 Mitsubishi Kasei Corp 抗不安薬
US5234948A (en) * 1990-03-14 1993-08-10 Mitsubishi Kasei Corporation Optically active alkylenedioxybenzene derivatives and their use in therapy
US5691325A (en) * 1994-01-14 1997-11-25 Sandyk; Reuven Method for ameliorating age-related disease conditions
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders

Also Published As

Publication number Publication date
US6160005A (en) 2000-12-12
DE69807586D1 (de) 2002-10-10
EP0884049B1 (en) 2002-09-04
EP0884049A1 (en) 1998-12-16
CA2238065C (en) 2006-07-11
CA2238065A1 (en) 1998-11-20
DE69807586T2 (de) 2003-06-26

Similar Documents

Publication Publication Date Title
RU2221790C2 (ru) Новые производные пиридазина и лекарственные средства, содержащие их в качестве эффективных ингредиентов
ES2082288T3 (es) Composiciones terapeuticas para administracion intranasal de ketorolaco.
CZ309247B6 (cs) 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru
UY27092A1 (es) Derivados del novedoso carbamato de quinuclidina y las composiciones medicinales que los contienen
NO2016005I1 (no) 2-okso-1-pyrrolidinderivater, farmasøytisk preparat og deres anvendelse for fremstilling av et medikament
MA28009A1 (fr) Derives de pyridazine et utilisation de ceux-ci en tant qu'agents therapeutiques
GT200000041A (es) Uso de inhibidores de cyp2d6 en terapias de combinacion.
SG157406A1 (en) Oral medicament for the modified release of at least one active principle, in multi-microcapsule form
CO5670327A2 (es) Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion
RU94044356A (ru) Применение 2-фенил-3-ароилбензотиофенов для увеличения экспрессии тромбомодулина для ингибирования тромботического расстройства, для увеличения активации протеина с
ES2092646T3 (es) Metanoantracenos como antagonistas de dopamina.
DE69333387D1 (de) Pharmazeutische Zusammensetzungen enthaltend Norastemizol.
BG104797A (en) Use of dexmedetomi dine for sedative effect in patients in an intensive care unit
DE69824313D1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
Douglas et al. The respiratory stimulant action of 5-hydroxytryptamine (serotonin) in the dog
EP1402890A4 (en) sulfonamide
ATE334590T1 (de) Anti-arrhythmische zusammensetzungen und behandlungsverfahren
UY26459A1 (es) 3,4-dihidroquinazolinas 5,6-disustituidas
ATE298240T1 (de) Getrennte dosis therapien mit gefässschädigender aktivität
ES2182504T3 (es) Bifenilsulfonilcianamidas, procedimiento para su preparacion y su utilizacion como medicamento.
AR022348A1 (es) Una composicion farmaceutica para el tratamiento de los sintomas del tracto urinario inferior
AR037543A1 (es) Metodo para la terapia del cancer y composicion farmaceutica
ES2105643T3 (es) Uso de la 2-(4-(4-clorofenil)ciclohexil)-3-hidroxi-1,4-naftoquinona para el tratamiento del cancer.
AR031846A1 (es) Combinacion de sustancias activas, medicamentos y formulaciones que la contienen, y uso de la misma para la preparacion de un medicamento para el tratamiento del dolor
CA2238065A1 (en) Medicament for circadian rhythm sleep disorder